Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer. We focus on targeted small molecule therapeutics. These are designed to disrupt the biochemical processes that drive the growth of cancers and development of auto-immune diseases.
Biochemical process: |
Sareum’s approach: |
|
Certain cancer cells are able to repair DNA damage making them resistant to chemotherapy and radiotherapy. |
Targeting the biochemical processes that enable cancer cells to repair damaged DNA. |
| Cancer cells develop differently from normal cells in many ways. In particular, cancer cells divide and grow much more rapidly than normal cells. | Targeting the biochemical processes that control cell growth and division. |
| Once a solid tumour reaches a certain size, it often connects to the body's lymph systems to remove waste. The lymph system often creates a route for a cancer to spread to other areas of the body (metastasis). | Disrupting the signals that are involved in the generation of new lymph vessels to a tumour. |
| Autoimmune and inflammatory diseases can be caused by excess production of cytokines (signalling molecules). | Targeting the signalling processes associated with these cytokines. |
Targeted cancer therapies disrupt specific biochemical processes necessary for tumour growth. These processes are specific to cancer cells and therefore may be:
Small molecule therapeutics are different to "biological" drugs such as antibodies. They can:
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
